跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 32 条关于
“DT120 (lysergide)”
全部
32
临床试验
17
药物
4
机构
0
资讯
11
3天前
Definium Therapeutics to Report Phase 3 Panorama Topline Results for LSD-Based Anxiety Drug DT120
上个月
APA 2026: Real-World GAD Treatment Gaps and Preclinical Safety Data for 5-HT2A Agonist DT120
3天前
Definium's DT120 ODT Hits Primary Endpoint in Second Phase 3 GAD Win, Setting Up First Psychedelic NDA for Anxiety
8个月前
MindMed Rebrands as Definium Therapeutics, Prepares for Three Phase 3 Psychedelic Therapy Readouts in 2026
去年
Xanomeline/Trospium Chloride Shows Cognitive Improvement in Schizophrenia; MindMed's LSD Trial Begins
去年
MindMed's MM120 Shows Promise in Phase 2b Trial for Generalized Anxiety Disorder
去年
MindMed's MM120 Advances in Phase III Trials for GAD and MDD, Stock Surges
11个月前
Single-Dose MM120 (LSD) Demonstrates Sustained Anxiety Relief in Phase 2b GAD Trial
2年前
MindMed's MM120 Receives FDA Breakthrough Therapy Designation for Generalized Anxiety Disorder
去年
MindMed Advances MM120 for GAD with Phase 3 Trials Underway
第 1 页,共 2 页
上一页
下一页